Content Search Navigation Sitemap About Who we are To maximise value and transform patient outcomes We have a portfolio of leading life science companies that are seeking to deliver transformational treatments to patients. Founded by the Wellcome Trust in 2012, our Investment Manager, Syncona Investment Management Limited (SIML), is a leading life science investor with a strong track record of significant value creation from exits. The team at SIML work in close partnership with world-class academic founders and experienced management teams, and have a broad range of scientific, operational, clinical, financial and commercial expertise. This enables them to effectively manage an increasingly mature portfolio, which is diversified across different stages of the development cycle and a range of therapeutic areas. Our balance sheet underpins our strategy, enabling us to fund our portfolio companies to key value inflection points over the next three years. Related content About View this section View this section Who we are NAV Growth Framework View this section View this section Who we are NAV Growth Framework Our people View this section View this section Board of Directors View this section View this section Board of Directors Portfolio View this section View this section Commercial companies Overview Autolus Therapeutics Late-stage clinical companies Overview Beacon Therapeutics Spur Therapeutics Clinical companies Overview iOnctura Quell Therapeutics Anaveon Mosaic Therapeutics Resolution Therapeutics Pre-clinical companies Overview Purespring Therapeutics Forcefield Therapeutics OMass Therapeutics Kesmalea Therapeutics Yellowstone Biosciences Slingshot Therapeutics Previous portfolio companies Overview Gyroscope Therapeutics Blue Earth Nightstar Neogene Therapeutics 14MG Azeria Therapeutics Clade Therapeutics View this section View this section Commercial companies Overview Autolus Therapeutics Overview Autolus Therapeutics Late-stage clinical companies Overview Beacon Therapeutics Spur Therapeutics Overview Beacon Therapeutics Spur Therapeutics Clinical companies Overview iOnctura Quell Therapeutics Anaveon Mosaic Therapeutics Resolution Therapeutics Overview iOnctura Quell Therapeutics Anaveon Mosaic Therapeutics Resolution Therapeutics Pre-clinical companies Overview Purespring Therapeutics Forcefield Therapeutics OMass Therapeutics Kesmalea Therapeutics Yellowstone Biosciences Slingshot Therapeutics Overview Purespring Therapeutics Forcefield Therapeutics OMass Therapeutics Kesmalea Therapeutics Yellowstone Biosciences Slingshot Therapeutics Previous portfolio companies Overview Gyroscope Therapeutics Blue Earth Nightstar Neogene Therapeutics 14MG Azeria Therapeutics Clade Therapeutics Overview Gyroscope Therapeutics Blue Earth Nightstar Neogene Therapeutics 14MG Azeria Therapeutics Clade Therapeutics Sustainability View this section View this section Our approach to sustainability reporting Syncona Fellowship Sustainability policies View this section View this section Our approach to sustainability reporting Syncona Fellowship Sustainability policies The Foundation News & insights View this section View this section News Insights & articles Publications & presentations View this section View this section News Insights & articles Publications & presentations Investors View this section View this section Results and presentations RNS and inside information Share price centre Governance Our Committees Financial calendar Events calendar Analysts and advisers Shareholder information Overview Regulatory publications Shareholder documents FAQs View this section View this section Results and presentations RNS and inside information Share price centre Governance Our Committees Financial calendar Events calendar Analysts and advisers Shareholder information Overview Regulatory publications Shareholder documents Overview Regulatory publications Shareholder documents FAQs Contact Search